Quantum Rx

Router calibrated on 1,601 real IBM Heron jobs — not simulation. GPU-first by default — and trial design runs QAOA on a real IBM Heron QPU: job dano0jg2fm4c73f4g6m0 on ibm_pittsburgh, 4,096 shots, 2026-09-20, sealed into the run itself. Open the sealed run →

Design the trial.
Carry the dossier.

Quantum Rx runs a five-step clinical-evidence chain — safety signal, evidence base, trial design, IND package, and a WORM clinical seal. Every record sealed.

Design a trial ↓

The problem we exist to solve

The science is hard.
The paperwork is fatal.

  • A trial too small to prove anything Size it wrong and you spend years to reach an inconclusive readout. The sample size is a decision you can't take back.
  • The right drug, the wrong patients Without companion diagnostics and stratification, a drug that works for a subgroup fails the whole population — and the program dies.
  • An IND that won't pass review FDA IND assembly and sealed records are unforgiving. A dossier with a gap is a clinical hold you didn't budget for.

What it seals

Five clinical steps.
Evidence to seal.

GPU-first by default. Step 03 prioritises trial arms with QAOA on a real IBM Heron QPU and seals the job id, the backend and the shot count with the result. Five sealed steps on the clinical-evidence chain.

  • Safety signal Pull adverse-event signals from openFDA FAERS so safety context sits on the same trail as the rest of the evidence.
  • Evidence base Assemble the clinical literature and prior findings your team will argue from — inspectable, not a black box.
  • Trial design Size the study, prioritise the arms, and lock power and dropout assumptions before enrollment spend.
  • IND package Assemble the IND section manifest under 21 CFR 312.23. It lists exactly what the sponsor still has to supply.
  • WORM clinical seal Write the clinical record to a tamper-evident seal so compliance can open the trail later without taking our word for it.

The trial designer

Size the study. Seal the design.

A working trial-design tool. Enter your endpoint and the designer computes the sample size to power it — adjusted for dropout — places the study on the development pipeline, runs the IND-readiness checklist, and seals the design.

Two-arm endpoint · power

Two-arm · superiorityPhase II ready
160 per arm
377 enrolled · 320 evaluable after 15% dropout
+15 pts
Absolute effect
1.96 / 0.84
z(α/2) / z(β)
377
Total enrollment
In-browser demonstration. Closed-form power calculation, sealed locally with WebCrypto SHA-256. Local illustration — not a live quantum run.

How clinical evidence is sealed

Signal. Evidence. Design.
IND. Seal.

  1. Safety signal

    openFDA FAERS adverse-event signal — safety context on the same trail as the rest of the evidence.

  2. Evidence base

    Assemble the clinical literature and prior findings your team will argue from.

  3. Trial design

    Closed-form power sets the sample size; arm prioritisation runs QAOA on a real IBM Heron QPU, and the run carries the job id, so a reviewer with instance access can pull the result from IBM directly.

  4. IND package

    Lay the sealed record against the IND sections of 21 CFR 312.23: what is in hand, and what still needs the sponsor’s own data. A manifest, not a filing.

  5. WORM clinical seal

    Safety signal, evidence, design and the IND manifest written to a tamper-evident record — signature and watermark a third party can verify. Anchored daily in Bitcoin and on Base.

Built for audit

Every design
gets sealed.

Signature and watermark on by default — so the dossier trail stays inspectable when review asks.

Talk through a trial

Tell us the endpoint and population. We will walk the design path with your team.

Back to home